Cresco Labs (CRLBF) Expected to Announce Earnings on Thursday

Key Points

• Cresco Labs is expected to announce its quarterly earnings on August 7th, with analysts predicting earnings of ($0.03) per share and revenue of $162 million.
• The company reported a negative net margin of 11.86% and a negative return on equity of 21.77% for its last earnings report in May.
• The stock price of Cresco Labs increased by 6.8%, closing at $0.64 and currently holds a market capitalization of approximately $314.94 million.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) is expected to release its earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $162.00 million for the quarter.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last announced its quarterly earnings data on Friday, May 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.01). The firm had revenue of $165.76 million during the quarter, compared to the consensus estimate of $164.37 million. Cresco Labs had a negative net margin of 11.86% and a negative return on equity of 21.77%. On average, analysts expect Cresco Labs to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cresco Labs Trading Up 3.2%

OTCMKTS:CRLBF traded up $0.02 during trading hours on Monday, hitting $0.64. 343,293 shares of the company were exchanged, compared to its average volume of 658,782. The company has a fifty day simple moving average of $0.56 and a 200 day simple moving average of $0.71. Cresco Labs has a one year low of $0.43 and a one year high of $2.05. The stock has a market capitalization of $314.25 million, a price-to-earnings ratio of -2.67 and a beta of 1.42. The company has a current ratio of 2.75, a quick ratio of 1.98 and a debt-to-equity ratio of 1.63.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group downgraded shares of Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a research note on Tuesday, June 3rd. Two research analysts have rated the stock with a hold rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy".

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.